Introduction {#s1}
============

The prevalence of osteoporotic fractures (OF), especially hip OF, has now become a significant public health burden due to the associated high morbidity, mortality and tremendous health care cost [@pone.0021835-Cooper1], [@pone.0021835-Gullberg1] The incidence of hip OF will reach 6.27 million worldwide with a resultant cost of \>\$34 billion by the year 2050 [@pone.0021835-Cooper1]. The major demographic change of hip OF will occur in Asia. In 1990, 26% of hip OF worldwide occurred in Asia, and this rate could rise to 37% by the year 2025 and to 45% by the year 2050 [@pone.0021835-Gullberg1]. Genetic factors play an important role in susceptibility to hip OF [@pone.0021835-Tranah1], [@pone.0021835-Styrkarsdottir1]. However, to date, the genetic determination of hip OF is still largely unknown.

A pathway-based association analysis approach is based on gene set enrichment analysis. The method ranks genes/SNPs genome-wide by the significance of association with a disease phenotype to generate a gene list, then uses a statistic enrichment score () to examine whether a particular group of genes/SNPs within a certain functional pathway is enriched at the top (or bottom) of the list more than would be expected by chance [@pone.0021835-Curtis1]. This approach considers critical information about the interaction of a set of functionally related genes and their joint effects, and could potentially improve the power to detect genetic variants working in functional pathways. The method may play a major role in genetic analyses of complex diseases; for a pathway that contributes to a disease\'s risk, a single genetic variant within that pathway may have only limited contribution to the risk that might not be detectable (in regular genetic association analyses) if not otherwise be detected at the whole pathway level. Recently, through this new powerful approach, we have identified two novel pathways for wrist BMD and femur geometry in US whites [@pone.0021835-Zhang1], [@pone.0021835-Chen1].

Previous studies revealed importance in the pathogenesis of bone metabolism for several individual genes/loci, or their transcripts and proteins in Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) pathway, for example, *TRAIL*, *TRAILR1*, *TRAILR2*, *CFLAR*, *RANK*, and *OPG* [@pone.0021835-Vaira1], [@pone.0021835-Sanjay1], [@pone.0021835-Yao1]. However, it is unknown if the TRAIL pathway may contribute to osteoporotic fracture risk at the whole pathway level. We therefore undertook a novel, pathway-based association study to assess contribution of the pathway to hip OF risk.

Materials and Methods {#s2}
=====================

Subjects {#s2a}
--------

The study was approved by the institutional review board of Xi\'an Jiaotong University. After signing an informed consent agreement, all subjects were assisted to complete a structured questionnaire including anthropometric variables, lifestyles, and medical history.

The sample consisted of 700 elderly Chinese Han subjects, including 350 with osteoporotic (low trauma) hip fractures (including 124 males and 226 females) and 350 controls (including 173 males and 177 females) (see [Table 1](#pone-0021835-t001){ref-type="table"} for the basic characteristics of these subjects). All the subjects were unrelated Chinese Han adults living in the city of Xi\'an and its neighboring areas. Inclusion criteria for cases were (i) onset age \>55 years, all female subjects were postmenopausal women; (ii) age \<80 years to minimize the effect due to age, since previous studies showed that approximately half of females aged 80 years or older have fractures [@pone.0021835-Ross1]; (iii) minimal or no trauma fractures, usually due to falls from standing height or less; (iv) fracture site at femoral neck or inter-trochanter regions; (v) hip fracture was identified/confirmed through diagnosis of orthopedic surgeons/radiologists according to radiological reports and X-rays. Patients with pathological fractures and high-impact fractures (such as due to motor vehicle accidents) were excluded.

10.1371/journal.pone.0021835.t001

###### Characteristics of the study subjects.

![](pone.0021835.t001){#pone-0021835-t001-1}

                 Case (n = 350)   Control (n = 350)
  ------------- ---------------- -------------------
  Age (years)     69.35 (7.41)      69.54 (6.09)
  Weight (kg)    59.15 (12.05)      59.61 (10.84)
  Height (cm)    162.84 (8.31)      159.41 (9.20)

Note: Data are shown as mean (standard deviation).

Healthy control subjects were selected from our established large database. They were geographically matched to the cases. Inclusion criteria for controls were: (i) age at exam \>55 years, without any fracture histories (all female controls were postmenopausal); and (ii) not suffering from chronic diseases and conditions that might potentially affect bone mass, structure, or metabolism. The criteria may ensure that controls are less likely to suffer OF during their remaining life span compared with the general populations. The diseases/conditions mentioned above included chronic disorders involving vital organs (heart, lung, liver, kidney, brain), serious metabolic diseases (diabetes, hypo- and hyper-parathyroidism, hyperthyroidism, etc.), other skeletal diseases (Paget disease, osteogenesis imperfecta, rheumatoid arthritis, etc.); chronic use of drugs affecting bone metabolism (e.g., hormone replacement therapy, corticosteroid therapy, anti-convulsant drugs), and malnutrition conditions (such as chronic diarrhea, chronic ulcerative colitis). In addition, subjects taking anti-resorptive or bone anabolic agents/drugs, such as bisphosphonates were also excluded.

Genotyping and quality control {#s2b}
------------------------------

Genomic DNA was extracted from peripheral blood leukocytes using a commercial isolation kit (Gentra systems, Minneapolis, MN, USA) following the standard protocols. SNP genotyping was performed using Affymetrix Human Mapping 500 K array set (Affymetrix, Santa Clara, CA, USA). Genotyping calls were determined from the fluorescent intensities using the dynamic model (DM) algorithm [@pone.0021835-Di1] as well as the B-RLMM (Bayesian Robust Linear Model with Mahalanobis Distance Classifier) algorithm [@pone.0021835-Rabbee1]. DM calls were used for quality control of the genotyping experiment. BRLMM calls were used for the following pathway-based analyses. SNPs with a sample call rate \<90%, with allele frequencies extremely deviating from Hardy-Weinberg equilibrium (*p*\<10^−7^) and having a minor allele frequency (MAF) \<0.01 in the total sample were discarded. The final SNP number for the analyses is 371,258. This SNP set covers 14,642 genes and yielded an average marker spacing of ∼7.9 kb throughout the human genome. Among these SNPs, 350 belong to the genes of the TRAIL pathway.

Statistical Analysis {#s2c}
--------------------

Statistical analyses on individual SNPs were first conducted by the Wald test implemented in Plink (version 1.03) [@pone.0021835-Purcell1] with age and sex as covariates. The main procedures of pathway-based analysis [@pone.0021835-Subramanian1] are briefly summarized as follows:

1.  Generation of gene-phenotype association rank and calculation of : Among all the SNPs of a given gene G~i~, the SNP achieving the smallest *p* value in the single-marker association tests was used to represent the magnitude of association evidence of the gene. We ranked all genes by sorting their statistic values from the largest to smallest, denoted as a vector of the gene list L (r~1~,r~2~,...,r~N~). "N" equals to the total gene number contained in the GeneChip® Human Mapping 500 K set arrays. "r" represents the gene-phenotype association statistic value. Then, a weighted Kolmogorov-Smirnov--like running-sum enrichment score () was calculated in Equation 1. For the given pathway S composed of N~S~ genes, by walking down the gene list L, we increased the running-sum statistic for the pathway when we encountered a gene in the S and decreased it when we encountered a gene not in the .Where and parameter *p* (designated as 1 here) is designed to give higher weight to genes with extreme statistic values. The magnitude of the increment depends on the correlation of the gene with the phenotype. In short, is the maximum deviation from zero encountered in the random walk. It will be high if the association signal is enriched at the top of list , reflected by the significance level of observed (i.e. nominal *p* value).

2.  Permutation and nominal significance assessment: The phenotype data was shuffled and permutation () was done to compute a through repeating steps (1)∼(2) to estimate the nominal *p* value. A total of 1,000 permutations were done to create a histogram of the corresponding enrichment scores for the given pathway/gene set . The nominal *p* value was estimated as the percentage of permutations whose were greater than the observed .

To detect possible population stratification that may lead to spurious association results, we used Structure 2.2 software (<http://pritch.bsd.uchicago.edu/software.html>) to investigate the potential population substructure/stratification of the sample. The program uses a Markov chain Monte Carlo (MCMC) algorithm to cluster individuals into different cryptic sub-populations on the basis of multi-locus genotype data [@pone.0021835-Pritchard1]. We performed the analysis assuming the number of population strata k = 2 and using 1,000 un-linked SNPs randomly selected genome-wide. To confirm the results achieved through Structure 2.2, we further tested population stratification in our sample using EIGENSOFT 2.0 software that uses both principal component analysis and a genomic control approach to correct possible statistical bias caused by ancestral differences [@pone.0021835-Price1], [@pone.0021835-Devlin1]. Reported *p* value was adjusted by the λ value estimated by genomic control method.

Results {#s3}
=======

Characteristics of study subjects {#s3a}
---------------------------------

Basic characteristics of the 700 subjects are presented in [Table 1](#pone-0021835-t001){ref-type="table"}. The STRUCTURE program revealed that all subjects in this Chinese sample were clustered together and could not be assigned into any subgroups, indicating that there was no significant population stratification within the sample. We also performed analysis using EIGENSOFT [@pone.0021835-Price1] and confirmed the homogeneity of the sample revealed by Structure; there is only one principal component that is significant in the principal component analysis (*p*\<0.001), suggesting only one population ancestry existing for our sample. Finally, we used the genomic control method [@pone.0021835-Devlin1] to estimate the λ value, which equals to 1.02, suggesting again there is no population stratification in the sample.

Pathway-based association analysis {#s3b}
----------------------------------

The TRAIL pathway, annotated by the Ambion GeneAssist Pathway Atlas ([Table 2](#pone-0021835-t002){ref-type="table"}), achieved a high NES of 1.76 with a *p* value of 0.01. Among the 38 genes in the TRAIL pathway, the gene with the most significant *p* value is *TNFSF10* (*TRAIL*, *p* = 1.70×10^−4^) ([Table 3](#pone-0021835-t003){ref-type="table"}). Another six genes in the TRAIL pathway, which also contribute positively to the *ES* (i.e., the genes that ranked before or at the point of *ES*, also denoted as "leading edge genes"), are: *CFLAR* (*c-FLIP*, *FLIP*, *p* = 3.17×10^−3^), *TNFSF11* (*RANKL*, *p* = 6.06×10^−3^), *TNFRSF11A* (*RANK*, *p* = 7.63×10^−3^), *TNFRSF10B* (*TRAILR2*, *p* = 1.07×10^−2^), *TRAF3* (*p* = 1.67×10^−2^), and *NFKB1* (*NF-κB1*, *p* = 2.04×10^−2^). Among the 38 genes in the TRAIL pathway, 4 genes, *NFKBIE*, *IKBKG*, *RELB*, *DIABLO*, were not covered by Affymetrix 500 k Array Set, and the SNPs of the *XIAP* and *APAF1* genes were discarded for failure of passing the quality control criteria ([Table 3](#pone-0021835-t003){ref-type="table"}).

10.1371/journal.pone.0021835.t002

###### Component genes in the TRAIL pathway.
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  Gene Symbol    Gene ID   Genome Location                                             Full name                                               Protein Name
  ------------- --------- ----------------- ----------------------------------------------------------------------------------------------- ------------------
  APAF1            317          12q23                                   apoptotic peptidase activating factor 1                                   APAF1
  BID              637         22q11.1                                   BH3 interacting domain death agonist                                      BID
  CBL              867         11q23.3                       Cas-Br-M (murine) ecotropic retroviral transforming sequence                         c-Cbl
  REL             5966        2p13-p12                        v-rel reticuloendotheliosis viral oncogene homolog (avian)                          c-Rel
  CASP3            836          4q34                                caspase 3, apoptosis-related cysteine peptidase                              Caspase3
  CASP8            841        2q33-q34                              caspase 8, apoptosis-related cysteine peptidase                              Caspase8
  CASP9            842         1p36.21                              caspase 9, apoptosis-related cysteine peptidase                              Caspase9
  CYCS            54205        7p15.3                                            cytochrome c, somatic                                            CytoC
  DAP3            7818          1q22                                          death associated protein 3                                           DAP3
  TNFRSF10C       8794        8p22-p21       tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain         DCRI
  TNFRSF10D       8793          8p21           tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain           DCR2
  FADD            8772         11q13.3                                 Fas (TNFRSF6)-associated via death domain                                   FADD
  CFLAR           8837        2q33-q34                                  CASP8 and FADD-like apoptosis regulator                                c-FLIP, FLIP
  NFKBIA          4792          14q13             nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha         I-KappaB-Alpha
  NFKBIB          4793         19q13.1            nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta          I-KappaB-Beta
  NFKBIE          4794         6p21.1            nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon       I-KappaB-Epsilon
  CHUK            1147        10q24-q25                              conserved helix-loop-helix ubiquitous kinase                               IKK-Alpha
  IKBKB           3551         8p11.2                 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta                 IKK-Beta

  Gene Symbol    Gene ID   Genome Location                                      Full name                                      Protein Name
  ------------- --------- ----------------- --------------------------------------------------------------------------------- --------------
  IKBKE           9641         1q32.1         inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon    I-KK-Epsilon
  IKBKG           8517          Xq28           inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma      I-KK-Gamma
  NFKB1           4790          4q24              nuclear factor of kappa light polypeptide gene enhancer in B-cells 1          NF-KappaB1
  NFKB2           4791          10q24        nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)    NF-KappaB2
  TNFRSF11B       4982          8q24                     tumor necrosis factor receptor superfamily, member 11b                    OPG
  TNFSF11         8600          13q14                     tumor necrosis factor (ligand) superfamily, member 11                   RANKL
  PARP1            142        1q41-q42                               poly (ADP-ribose) polymerase 1                                PARP
  TNFRSF11A       8792         18q22.1           tumor necrosis factor receptor superfamily, member 11a, NFKB activator            RANK
  RELA            5970          11q13                 v-rel reticuloendotheliosis viral oncogene homolog A (avian)                 RelA
  RELB            5971        19q13.32                    v-rel reticuloendotheliosis viral oncogene homolog B                     RelB
  DIABLO          56616       12q24.31                                 diablo homolog (Drosophila)                                 SMAC
  TRAF1           7185        9q33-q34                              TNF receptor-associated factor 1                              TRAF1
  TRAF2           7186          9q34                                TNF receptor-associated factor 2                              TRAF2
  TRAF3           7187        14q32.32                              TNF receptor-associated factor 3                              TRAF3
  TRAF4           9618        17q11-q12                             TNF receptor-associated factor 4                              TRAF4
  TRAF6           7189          11p12                               TNF receptor-associated factor 6                              TRAF6
  TNFSF10         8743          3q26                      tumor necrosis factor (ligand) superfamily, member 10                   TRAIL
  TNFRSF10A       8797          8p21                     tumor necrosis factor receptor superfamily, member 10a                  TRAILR1
  TNFRSF10B       8795        8p22-p21                   tumor necrosis factor receptor superfamily, member 10b                  TRAILR2
  XIAP             331          Xq25                                 X-linked inhibitor of apoptosis                               XIAP

Note: (1) TRAIL, TNF-Related Apoptosis-Inducing Ligand.

\(2\) The Gene ID was retrieved from NCBI GenBank (<http://www.ncbi.nlm.nih.gov/Genbank/>).

10.1371/journal.pone.0021835.t003

###### Association Results for the SNPs of Top Significance for Each Gene in the TRAIL Pathway.

![](pone.0021835.t003){#pone-0021835-t003-3}

  Gene                  SNP         Chr.    Physical location        Role           P value     Allele[a](#nt105){ref-type="table-fn"}   MAF[b](#nt106){ref-type="table-fn"}   OR (95%CI)[c](#nt107){ref-type="table-fn"}
  --------------- --------------- -------- ------------------- ----------------- ------------- ---------------------------------------- ------------------------------------- --------------------------------------------
  APAF1                 \-           12            \-                 \-              \-                          \-                                     \-                                        \-
  BID                rs424708        22         16588746          Downstream        0.07899                       C                                     0.012                              0.35 (0.11--1.13)
  CBL                rs4938638       11         118580639         Downstream        0.3039                        C                                     0.127                              0.84 (0.60--1.17)
  REL                rs842627        2          60994311          Downstream        0.08129                       A                                     0.127                              1.38 (0.96--1.99)
  CASP3              rs4862379       4          185849707         Downstream        0.1001                        C                                     0.081                              1.40 (0.94--2.09)
  CASP8              rs6723097       2          201954124           Intron          0.4147                        C                                     0.468                              0.91 (0.73--1.14)
  CASP9              rs2042369       1          15715831            Intron          0.1818                        A                                     0.039                              0.66 (0.36--1.22)
  CYCS              rs10239907       7          24905619           Upstream         0.1457                        C                                     0.290                              1.20 (0.94--1.53)
  DAP3               rs821551        1          152501653           Intron          0.3871                        A                                     0.180                              0.88 (0.67--1.17)
  TNFRSF10C         rs10111172       8          23025036            Intron           0.24                         C                                     0.173                              0.84 (0.64--1.12)
  TNFRSF10D          rs4278155       8          23052724            Intron            0.4                         C                                     0.441                              0.91 (0.73--1.13)
  FADD              rs11604809       11         69722984          Downstream        0.9726                        C                                     0.466                              1.00 (0.81--1.23)
  **CFLAR**        **rs719126**    **2**      **201726075**       **Intron**      **0.00317**                   **A**                                 **0.015**                          **0.05 (0.01--0.36)**
  NFKBIA            rs10132268       14         35017365           Upstream         0.1129                        A                                     0.431                              1.19 (0.96--1.46)
  NFKBIB             rs2241704       19         44088175            Intron          0.9237                        A                                     0.120                              0.98 (0.71--1.37)
  NFKBIE                \-           6             \-                 \-              \-                          \-                                                                               \-
  CHUK               rs7909855       10         101957202           Intron          0.2635                        C                                     0.460                              0.88 (0.70--1.10)
  IKBKB             rs10094577       8          42206733           Upstream         0.4423                        C                                     0.013                              0.68 (0.25--1.83)
  IKBKE              rs2871360       1          203065616         Downstream        0.2916                        C                                     0.428                              0.89 (0.71--1.11)
  IKBKG                 \-           X             \-                 \-              \-                          \-                                                                               \-
  **NFKB1**        **rs6533015**   **4**      **103712711**      **Upstream**     **0.02041**                   **C**                                 **0.336**                          **0.76 (0.60--0.96)**
  NFKB2             rs11574851       10         104150949         Coding exon       0.4637                        C                                     0.058                              1.20 (0.74--1.96)
  TNFRSF11B          rs7816831       8          119792244          Upstream         0.07085                       C                                     0.201                              1.29 (0.98--1.69)
  **TNFSF11**      **rs9594738**   **13**     **41850145**       **Upstream**     **0.00606**                   **C**                                 **0.080**                          **0.55 (0.36--0.84)**
  PARP1              rs3219058       1          222879529           Intron          0.1564                        C                                     0.318                              0.85 (0.67--1.07)
  **TNFRSF11A**    **rs1805034**   **18**     **58178221**      **Coding exon**   **0.00763**                   **C**                                 **0.314**                          **0.72 (0.57--0.92)**
  RELA               rs1466462       11         65175940            Intron          0.7124                        A                                     0.193                              0.95 (0.72--1.25)
  RELB                  \-           19            \-                 \-              \-                          \-                                                                               \-
  DIABLO                \-           12            \-                 \-              \-                          \-                                                                               \-
  TRAF1              rs2416804       9          120755950           Intron          0.7757                        C                                     0.472                              1.03 (0.83--1.28)

  Gene                  SNP          Chr.    Physical location        Role          P value     Allele[a](#nt105){ref-type="table-fn"}   MAF[b](#nt106){ref-type="table-fn"}   OR (95%CI)[c](#nt107){ref-type="table-fn"}
  --------------- ---------------- -------- ------------------- ---------------- ------------- ---------------------------------------- ------------------------------------- --------------------------------------------
  TRAF2              rs2811757        9          137071341           Intron         0.4854                        A                                     0.131                              0.88 (0.61--1.26)
  **TRAF3**        **rs11160706**   **14**     **102431489**       **Intron**     **0.01667**                   **A**                                 **0.341**                          **0.75 (0.60--0.95)**
  TRAF4              rs4794836        17         24106837          Downstream       0.4349                        A                                     0.253                              1.10 (0.87--1.40)
  TRAF6              rs2201845        11         36512834          Downstream       0.3038                        C                                     0.040                              0.74 (0.42--1.31)
  **TNFSF10**      **rs6445063**    **3**      **173676334**     **Downstream**   **0.00017**                   **A**                                 **0.024**                         **16.51 (3.83--71.24)**
  TNFRSF10A          rs6557634        8          23116201            Intron         0.1974                        C                                     0.022                              1.65 (0.77--3.51)
  **TNFRSF10B**    **rs4259415**    **8**      **22957513**        **Intron**     **0.0107**                    **A**                                 **0.298**                          **1.37 (1.08--1.74)**
  XIAP                   \-           X             \-                 \-             \-                          \-                                                                               \-

Note: (1) The SNPs significantly associated with hip OF are shown in bold.

\(2\) ^a^Minor allele of each SNP.

\(3\) ^b^Minor allele frequency calculated in our sample.

\(4\) ^c^Per-allele effect size of the minor allele is expressed by odds ratio (OR) and the 95% confidence interval of OR.

For the top SNP of each gene, the effect size of the minor allele is expressed by odds ratio (OR) derived from logistic regression analyses. The OR value is interpreted in the standard manner. A value of 1.0 indicates no effect. A value greater than 1.0 indicates that the minor allele is associated with an increased hip OF risk, and a value less than 1.0 implies that the minor allele is associated with a decreased risk, hence may be protective. Among the 7 SNPs representing the 7 leading edge genes, 5 SNPs had the protective minor allele. They are: *rs719126* of the *CFLAR* gene (minor allele A, OR = 0.05, 95%CI: 0.01--0.36), *rs6533015* of the *NFKB1* gene (minor allele C,OR = 0.76, 95%CI: 0.60--0.96), *rs9594738* of the *TNFSF11* gene (minor allele C, OR = 0.55, 95%CI: 0.36--0.84), *rs1805034* of the *TNFRSF11A* gene (minor allele C, OR = 0.72, 95%CI: 0.57--0.92), and *rs11160706* of the *TRAF3* gene (minor allele A, OR = 0.75, 95%CI: 0.60--0.95). The other two SNPs, *rs6445063* in the *TNFSF10* (*TRAIL*) gene and *rs4259415* in the *TNFRSF10B* (*TRAILR2*) gene, had a minor allele "A" with OR values of 16.51 (95%CI: 3.83--71.24) and 1.37 (95%CI: 1.08--1.74), respectively. The minor alleles of these two SNPs are significantly associated with an increased risk of hip OF (*P*\<0.05) ([Table 3](#pone-0021835-t003){ref-type="table"}).

Discussion {#s4}
==========

In this study, the TRAIL pathway was shown to be significantly associated with hip OF (*p* = 0.01) according to the pathway-based association analysis. This is the first time that the TRAIL pathway is implicated as an underlying factor for hip OF in Chinese. The pathway may contribute to bone mass variation via regulating osteoclast metabolism; previous findings have shown that the TRAIL pathway play roles in modulating the differentiation, function, survival and/or apoptosis of osteoclasts [@pone.0021835-Colucci1], [@pone.0021835-Feng1], which may in turn accelerate bone resorption and consequently the susceptibility to hip OF. The core process of TRAIL and the functional interactions among the genes in the TRAIL pathway are depicted in [Figure 1](#pone-0021835-g001){ref-type="fig"}.

![TRAIL pathway and the gene-gene interaction.\
The binding of TRAIL to TRAILR2 may induce the apoptosis of osteoclast. Increased c-FLIP levels may decrease the apoptosis of Osteoclast. The osteoclast apoptosis signal transduced by TRAIL/TRAILR2 was transformed to activate NF-κB. A key step in downstream signaling of RANKL/RANK is binding of TRAFs to RANK. Stimulation of RANK also results in strong NF-κB activation. NF-κB1(p50) is an important signal for osteoclast development and osteoclast function.](pone.0021835.g001){#pone-0021835-g001}

*TRAIL*, also known as *Apo2L*, is a widely recognized member of the tumor necrosis factor (TNF) ligand family [@pone.0021835-Pitti1], [@pone.0021835-Wiley1]. *TRAIL* is a typical type II membrane protein, binds to aggregates type I transmembrane receptors with cytoplasmic death domains (DD), which ultimately activate a protease cascade leading to apoptosis [@pone.0021835-Pan1]. Interacting with five different receptors of the TNF receptor superfamily, *TRAILR1*, *TRAILR2*, *TRAILR3*, *TRAILR4* and *OPG*, the ligand is expressed constitutively in a wide range of tissues [@pone.0021835-Wiley1], [@pone.0021835-Chamoux1], [@pone.0021835-Zauli1], including bone-related cells, such as osteoclast or osteoclast precursors. The binding of *TRAIL* to *TRAILR2* (DR5), which contains a conserved death domain (DD), may induce the apoptosis of osteoclast [@pone.0021835-Colucci1]. This may play an important role in the etiology of hip OF. *TRAIL* induces apoptosis in human differentiated osteoclasts by means of *TRAILR2*, and activates an intracellular pathway involving caspase-8 and Bid cleavage in the active forms [@pone.0021835-Colucci1]. However, in this study, SNP *rs6445063* from *TNFSF10 (TRAIL) gene* and SNP *rs4259415* from *TNFRSF10B* (*TRAILR2*) gene of the pathway had minor alleles (A) that are associated with an increased risk of hip OF, with the ORs (odds ratios) of 16.51 (95%CI:3.83--71.24) and 1.37 (95%CI:1.08--1.74), respectively. SNP *rs6445063* is located on chromosome 3q26.31 and has never been studied previously. SNP *rs4259415* is located on chromosome 8p21.3 and functions as intronic enhancer. According to the FASTSNP program (<http://fastsnp.ibms.sinica.edu.tw>), a change of "G→A" at *rs4259415* may lead to alter the binding sites for transcription factor from GATA-1 to CdxA and TATA, which may change the function of apoptosis related *TRAILR2* gene and accordingly alter the apoptosis of osteoclast. Furthermore, the apoptosis induced by death receptors can be modulated at several levels. Intracellular anti-apoptotic molecules can block the apoptotic signaling pathway. Soluble receptors inhibit TRAIL-mediated apoptosis in part by increasing baseline levels of CFLAR (c-FLIP), which competes with caspase-8 for binding to FADD, and inhibits active caspases [@pone.0021835-Tschopp1]. Increased c-FLIP levels following exposure to soluble factors may decrease the apoptosis of osteoclast. Intracellular anti-apoptotic molecules can also divert the apoptosis signaling into alternative responses, i.e., the proliferation/survival of osteoclast via activating NF-κB [@pone.0021835-Feng1]. Although lack of bone phenotype in mice with gene deletion of *TRAIL* was observed by Sedger et al [@pone.0021835-Sedger1], Yen et al [@pone.0021835-Yen1] showed that *TRAIL* can induce osteoclast formation via direct engagement with the *TRAIL* death receptor. Yen et al [@pone.0021835-Yen1], [@pone.0021835-Hsu1] suggested that TRAIL-induced osteoclastogenesisis was dependent on activation of NF-κB, ERK, and p38 MAP kinase and TRAF6 dependent. However *TRAF6* was not found to contribute positively to the ES as *TRAF3* in this study, suggests that there may be other factors that also can function in this capacity.

As the soluble decoy receptor of *TRAIL*, *OPG* was originally identified as a decoy receptor for *RANKL* [@pone.0021835-Lacey1] later found to be able to bind *TRAIL* [@pone.0021835-Emery1]. *OPG* acts as antagonist for osteoclast apoptosis induced by *TRAIL*. But when *OPG* binds to the *RANKL* on the surface of osteoblast/bone matrix, it prevents *RANKL* from binding to its receptor, RANK, which inhibits the formation, activation and survival of multinucleated osteoclasts. In this process, the *RANKL/OPG* ratio is an important determinant of bone mass and skeletal integrity [@pone.0021835-Grimaud1]. Up-regulation of the *RANKL* gene increases the RANKL/OPG ratio and enhances bone loss [@pone.0021835-Grimaud1]. Our study found a significant association of SNPs (*rs9594738* and *rs1805034*) of *RANKL* and *RANK* with hip OF.

*NF-κB1* (p50) is a subunit of NF-κB transcriptional factor complex. The balance of survival (anti-apoptotic) and death (apoptotic) signals through NF-κB activation cascades results in normal bone homeostasis and healthy remodeling [@pone.0021835-Xu1]. NF-κB activation through RANK/RANKL signal pathway is closely related with osteoporosis and the bone resorbing activity of osteoclasts [@pone.0021835-Wakeyama1]. After *RANKL* binds to *RANK*, a key step in downstream signaling is binding of TRAFs to specific sites of the cytoplasmic domain of *RANK* [@pone.0021835-Feng1], [@pone.0021835-Hauer1], [@pone.0021835-Darnay1]. Stimulation of *RANK* results in strong *NF-κB* activation. *NF-κB1(p50)* is an important signal for osteoclast development and osteoclast function. Moreover, NF-κB can be activated in many signal cascades related to bone metabolism, e.g., NF-κB activation through the Fas/FasL system leads to enhanced osteoclastogenesis and reduced apoptosis, and it may also cause apoptotic cell death in osteoblasts [@pone.0021835-Mogi1].

Population stratification is an important source of spurious association in genetic association studies [@pone.0021835-Thomas1], [@pone.0021835-Chanock1]. However, these factors are unlikely to exist in our sample to interfere with our pathway-based association results. Our cohort came from an apparently homogenous Chinese north-west Han ethnicity population, living in Xi\'an city and its neighboring areas. More importantly, in the analyses using Structure 2.2 [@pone.0021835-Pritchard2], all subjects used in our study consistently clustered together as a single group, suggesting no significant population substructure. In the analysis using EIGENSTRAT [@pone.0021835-Price1], the measure for population stratification, λ, was very close to 1, which also suggests no stratification in our cohort. For the above reasons, our association results are unlikely to be plagued by spurious associations due to population admixture/stratification.

In summary, we applied a pathway-based analysis method to identify functional gene sets associated with hip OF. The significant enrichment of the TRAIL pathway genes among the top ranking genes associated with hip OF, together with the pathway\'s functional relevance to bone metabolism, strongly supports the important role of TRAIL in human hip OF risk. Further detailed and specific functional studies of the TRAIL pathway will be pursued to provide new insights into the etiology of hip OF.
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